Intranasal Corticosteroids of the New Generation in the Therapy of the Children with Allergic Rhinitis
DOI:
https://doi.org/10.5457/ams.v39i2.160Keywords:
allergic rhinitis, children, intranasal corticosteroidsAbstract
According to a recent epidemiological studies the avarage rate of prevalence of allergic rhinitis (AR) in children, in USA is between 20- 40% and in Western Europe up to 20%. The disease most ferquently appeared in children age 4 to 11. In this study authors analysed the results of the recent studies according to the literature data about the efficacy and safety of the intranasal corticosteroids in children with allergic rhinitis. These drugs as well as antihistamines and decongestants, are the first line therapy choice in allergic rhinitis. According to the numerous experimental and clinical studies, intranasal corticosteroids of the new generation decrease the intensity of allergic inflammmation by induction of apoptosis of eosinopils and by decreased expression of intercelular adhesion molecules (ICAM) and proinflammatory mediators as TNF-alpha, IL-8, Il-4, Il-5. All studies in children showed no significant bioavailability and no effect on plasma cortisol level in therapy with new generation of intranasal corticosteroids.The leading symptom of allergic rhinitis, nasal congestion, was markedly reduced.Intranasal corticosteroids decrease the intensity of simptoms in comorbid diseases in children as sinusitis, secretory otitis media and asthma attacks. The local adverse effects of intranasal corticosteroids such as iritabillity of nasal mucosa, dryness of the nose and mouth, headache and epistaxis are rare. The results of recent studies showed that intranasal corticosteroids of the new generations have high safety profile and are recommended as the first line therapy choice in children with moderate to severe type of persisent allergic rhinitis.
Downloads
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
